Oxford University and partners win government funding to evaluate Paige Prostate Cancer Detection System

Paige Prostate automatically detects and highlights areas of suspicious tissue, allowing the pathologist to quickly identify if cancer is present in the patient biopsy. The software also measures and grades the severity of tumours it detects, all of which assists the pathologist in accurately and efficiently diagnosing cancer and influencing important treatment decisions in patients with prostate cancer.

This award means that Oxford University and its NHS partners North Bristol NHS Trust and University Hospitals Coventry and Warwickshire, together with Oxford University Hospitals NHS Foundation Trust, will use Paige Prostate prospectively in a real-world cancer laboratory setting, taking the technology one step closer to widespread use in the NHS to benefit patients.

Oxford University was one of five lead organisations to receive Phase 4 funding, which was announced by the Health and Social Care Secretary Matt Hancock on 16 June 2021. The AI Award is a significant government initiative making £140 million available over four years to accelerate the testing and evaluation of artificial intelligence technologies which meet the aims set out in the NHS Long Term Plan.

Professor Clare Verrill from Oxford University’s Nuffield Department of Surgical Sciences and Oxford University Hospitals NHS Foundation Trust and Principle Investigator on the project, said, 'I see this both as a natural evolution and key transformational point for histopathology. With this award we can advance the adoption of powerful technology to help pathologists by demonstrating the system-wide potential of using AI-based diagnostic systems in routine reporting.'

Dr Margaret Horton, Business Lead for Europe at Paige and a co-Investigator on the project said, 'The NHSx program provides the ideal catalyst for the system-wide adoption of artificial intelligence-based technologies such as Paige Prostate to improve efficiency, accuracy and patient and staff experiences. The pathologists and principal investigators in this study are global leaders in the implementation of digital pathology and utilising innovation to advance diagnostic service delivery.'

Dr Leo Grady, Chief Executive Officer of Paige, commented, 'Computational pathology for diagnostics has clear potential to increase diagnostic accuracy and more efficiently utilise scarce diagnostic resources in the NHS and in other health systems around the world. The next clear step to bring this to routine practice is pathologist-led implementation in every day practice to demonstrate and measure benefits to patients, laboratories and the NHS. This exciting work with Oxford University and their NHS partners is a tremendous achievement and Paige is very proud to be working with them in transforming the important work that pathologists do.'

The AI Award is one of the programmes that make up the NHS AI Lab, led by NHSX and delivered in partnership with the Accelerated Access Collaborative (AAC) and National Institute for Health Research (NIHR).

Dan Bamford, Deputy Director AI Award, Accelerated Access Collaborative, said, ‘Congratulations to Oxford University and its NHS partners on their success as one of our winners of the AI Award. We look forward to working with them as they develop and test the Paige Prostate technology further, so that more patients can benefit from this cutting-edge artificial intelligence.’

Dr Indra Joshi, Director of AI, NHSX, said, ‘With this latest round of AI Award winners, we now have an incredible breadth of expertise across a wide range of clinical and operational areas. Through this award, Oxford University and its NHS partners will be at the forefront of applying artificial intelligence in new ways to transform health and care.’

This is a histopathologist-led study and builds on investments made in digital pathology technology and infrastructure as part of the PathLAKE Centre of Excellence for digital pathology and artificial intelligence. Professor Verrill’s experimental pathology work is supported by the NIHR Oxford Biomedical Research Centre.